TUFM: Potential Drug Target Or Cancer Biomarker (G7284)

Target Name: TUFM

NCBI ID: G7284

TUFM

TUFM: Potential Drug Target Or Cancer Biomarker

TUFM (Tumor-associated extracellular matrix protein) is a protein that is expressed in various tissues of the body, including the skin, bone, and connective tissue. It is a member of the extracellular matrix (ECM) family and is involved in the regulation of cell adhesion, migration, and invasion. TUFM has also been shown to play a role in cancer progression and the development of various types of cancer. As a result, TUFM has potential as a drug target or biomarker for the treatment of cancer.

TUFM is a 21-kDa protein that is expressed in a variety of tissues, including the skin, hair, nails, and bones. It is a member of the ECM family and is responsible for the production and distribution of the ECM components in the body. The ECM is a complex structure that is composed of a variety of proteins, including cytoskeletal components, adhesion molecules, and enzymes that play important roles in tissue structure and function. TUFM is one of the proteins that is involved in the regulation of these processes.

In cancer, TUFM has been shown to play a role in the development and progression of various types of cancer. For example, TUFM has been shown to be involved in the regulation of cell adhesion and migration, which are critical processes that allow cancer cells to spread and invade other tissues. In addition, TUFM has also been shown to play a role in the regulation of the angiogenic switch, which is the process by which cancer cells transition from a state of dormancy to a state of active growth and proliferation.

As a result of its involvement in these processes, TUFM has potential as a drug target or biomarker for the treatment of cancer. For example, studies have shown that inhibiting TUFM can lead to the downregulation of cell adhesion and migration, which can lead to the inhibition of cancer cell growth and the development of a more aggressive cancer phenotype. Additionally, TUFM has also been shown to be involved in the regulation of the angiogenic switch, which can be targeted by drugs that inhibit the activity of angiogenic factors, such as TGF-β1.

In addition to its potential as a drug target or biomarker, TUFM also has potential as a diagnostic tool for the detection of cancer. For example, TUFM has been shown to be expressed in a variety of tissues and has been used as a marker for the diagnosis of various types of cancer, including breast, lung, and ovarian cancers. In addition, TUFM has also been shown to be expressed in the blood vessels of cancer cells, which can be used as a marker for the diagnosis of cancer-related complications, such as metastasis.

In conclusion, TUFM is a protein that is involved in the regulation of various processes in the body, including cell adhesion, migration, and the angiogenic switch. As a result, TUFM has potential as a drug target or biomarker for the treatment of cancer, as well as a diagnostic tool for the detection of cancer. Further research is needed to fully understand the role of TUFM in these processes and to develop effective treatments and diagnostic tools for the treatment of cancer.

Protein Name: Tu Translation Elongation Factor, Mitochondrial

Functions: Promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. Also plays a role in the regulation of autophagy and innate immunity. Recruits ATG5-ATG12 and NLRX1 at mitochondria and serves as a checkpoint of the RIGI-MAVS pathway. In turn, inhibits RLR-mediated type I interferon while promoting autophagy

The "TUFM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TUFM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets